The challenges of translation-Reference-Cited by-同舟云学术

The challenges of translation

Published:2019-10-18 Issue:12 Volume:11 Page:
ISSN:1757-4676
Container-title:EMBO Molecular Medicine
language:en
Short-container-title:EMBO Mol Med

Author:

Salih Helmut R¹^ORCID,Jung Gundram²³

Affiliation:

1. Clinical Collaboration Unit Translational Immunology German Cancer Consortium (DKTK) Department of Internal Medicine University of Tübingen Tübingen Germany

2. Department of Immunology Institute for Cell Biology University of Tübingen Tübingen Germany

3. German Cancer Consortium (DKTK) DKFZ partner site Tübingen Tübingen Germany

Publisher

EMBO

Subject

Molecular Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.15252/emmm.201910874

Reference12 articles.

1. Combination of T‐cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication;Ganss R;Cancer Res,2002

2. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity.

3. The storm has cleared: lessons from the CD28 superagonist TGN1412 trial

4. Induction of cytotoxicity in resting human T lymphocytes bound to tumor cells by antibody heteroconjugates.

5. Local immunotherapy of glioma patients with a combination of 2 bispecific antibody fragments and resting autologous lymphocytes: Evidence for in situ T-cell activation and therapeutic efficacy

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Optimizing the manufacturing and antitumour response of CAR T therapy;Nature Reviews Bioengineering;2023-02-14

2. Mass spectrometry for quality control of bispecific antibodies after SDS‐PAGE in‐gel digestion;Biotechnology and Bioengineering;2021-05-14

3. An IgG‐based bispecific antibody for improved dual targeting in PSMA‐positive cancer;EMBO Molecular Medicine;2020-12-29

4. Protocol of a prospective, multicentre phase I study to evaluate the safety, tolerability and preliminary efficacy of the bispecific PSMAxCD3 antibody CC-1 in patients with castration-resistant prostate carcinoma;BMJ Open;2020-10